Merck said the pivotal phase III KEYNOTE-042 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (including nonsquamous or squamous histologies) met its primary endpoint of overall survival.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
